Dementia Institute AI Repurposes Existing Drugs for MND
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UK Dementia Research Institute in Edinburgh is using AI to analyze patient voice recordings, eye scans, and stem‑cell‑derived neurons to locate existing drugs that may treat motor neurone disease and other brain disorders.
- MND‑SMART trial tests multiple repurposed drugs at once, a departure from the traditional single‑drug‑plus‑placebo design.
- Steven Barrett, a 10‑year MND patient, says the AI‑driven trials give him “a bright light” of hope for himself and others.
- Prof Siddarthan Chandran notes that roughly 1,500 approved drugs could be screened by the AI, potentially turning a decades‑long search into years.
- AI algorithms have been trained to recognize disease signatures and predict which drugs can convert those signatures to a healthy state, guiding which compounds move to clinical testing.
Why it matters: Patients with motor neurone disease and other brain disorders could receive effective treatments within years instead of decades, while the Institute leverages over 1,500 approved drugs, cutting development costs and speeding clinical trials.
Ask SkimNews
